A molecular subtype of glioblastoma characterized by the presence of NF1 mutations.
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
The documentation for mesenchymal glioblastoma is limited due to its rarity and the complexity of glioblastoma subtypes. As this condition affects fewer individuals, systematic clinical studies have been sparse, making comprehensive data collection challenging. Additionally, the genetic basis is still being explored, which contributes to the gaps in clinical characterization. This situation is not uncommon in rare diseases, where ongoing research is crucial for better understanding and management.
To navigate your care effectively, seek a neuro-oncologist with specific expertise in glioblastoma subtypes. They can provide tailored treatment options and monitor your condition closely. Additionally, consider reaching out to organizations like the National Brain Tumor Society (https://braintumor.org) for resources and support. Although there are no patient organizations specifically identified for mesenchymal glioblastoma, participating in clinical trials may also provide access to cutting-edge treatments. Genetic counseling could be beneficial to understand any potential hereditary implications, even in the absence of identified genes.
There are several orphan drugs designated for mesenchymal glioblastoma, including (1-hydroxy-2-oxopiperidin-3-yl)phosphonic acid and anti-beta1 integrin monoclonal antibody, among others. Currently, there are three active clinical trials investigating potential treatments for this condition. For more information on these trials, please visit the ClinicalTrials.gov search page at https://clinicaltrials.gov/search?cond=mesenchymal%20glioblastoma. This ongoing research offers hope for improved treatment options in the future.
Actionable guidance for navigating care for mesenchymal glioblastoma
To navigate your care effectively, seek a neuro-oncologist with specific expertise in glioblastoma subtypes. They can provide tailored treatment options and monitor your condition closely. Additionally, consider reaching out to organizations like the National Brain Tumor Society (https://braintumor.org) for resources and support. Although there are no patient organizations specifically identified for mesenchymal glioblastoma, participating in clinical trials may also provide access to cutting-edge treatments. Genetic counseling could be beneficial to understand any potential hereditary implications, even in the absence of identified genes.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 5 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.